Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/101716
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorChen, Yen_US
dc.creatorWang, Ben_US
dc.creatorChen, Yen_US
dc.creatorWu, Qen_US
dc.creatorLai, WFen_US
dc.creatorWei, Len_US
dc.creatorNandakumar, KSen_US
dc.creatorLiu, Den_US
dc.date.accessioned2023-09-18T07:41:38Z-
dc.date.available2023-09-18T07:41:38Z-
dc.identifier.urihttp://hdl.handle.net/10397/101716-
dc.language.isoenen_US
dc.publisherFrontiers Research Foundationen_US
dc.rightsCopyright © 2022 Chen, Wang, Chen, Wu, Lai, Wei, Nandakumar and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsThe following publication Chen, Y., Wang, B., Chen, Y., Wu, Q., Lai, W. F., Wei, L., ... & Liu, D. (2022). HAPLN1 affects cell viability and promotes the pro-inflammatory phenotype of fibroblast-like synoviocytes. Frontiers in Immunology, 13, 888612 is available at https://doi.org/10.3389/fimmu.2022.888612.en_US
dc.subjectCell migrationen_US
dc.subjectCell viabilityen_US
dc.subjectFibroblast-like synoviocytesen_US
dc.subjectHyaluronan and proteoglycan link protein 1en_US
dc.subjectPathogenesisen_US
dc.subjectRheumatoid arthritisen_US
dc.titleHAPLN1 affects cell viability and promotes the pro-inflammatory phenotype of fibroblast-like synoviocytesen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume13en_US
dc.identifier.doi10.3389/fimmu.2022.888612en_US
dcterms.abstractHAPLN1 maintains aggregation and the binding activity of extracellular matrix (ECM) molecules (such as hyaluronic acid and proteoglycan) to stabilize the macromolecular structure of the ECM. An increase in HAPLN1 expression is observed in a few types of musculoskeletal diseases including rheumatoid arthritis (RA); however, its functions are obscure. This study examined the role of HAPLN1 in determining the viability, proliferation, mobility, and pro-inflammatory phenotype of RA- fibroblast-like synoviocytes (RA-FLSs) by using small interfering RNA (siHAPLN1), over-expression vector (HAPLN1OE), and a recombinant HAPLN1 (rHAPLN1) protein. HAPLN1 was found to promote proliferation but inhibit RA-FLS migration. Metformin, an AMPK activator, was previously found by us to be able to inhibit FLS activation but promote HAPLN1 secretion. In this study, we confirmed the up-regulation of HAPLN1 in RA patients, and found the positive relationship between HAPLN1 expression and the AMPK level. Treatment with either si-HAPLN1 or HAPLN1OE down-regulated the expression of AMPK-ɑ gene, although up-regulation of the level of p-AMPK-ɑ was observed in RA-FLSs. si-HAPLN1 down-regulated the expression of proinflammatory factors like TNF-ɑ, MMPs, and IL-6, while HAPLN1OE up-regulated their levels. qPCR assay indicated that the levels of TGF-β, ACAN, fibronectin, collagen II, and Ki-67 were down-regulated upon si-HAPLN1 treatment, while HAPLN1OE treatment led to up-regulation of ACAN and Ki-67 and down-regulation of cyclin-D1. Proteomics of si-HAPLN1, rHAPLN1, and mRNA-Seq analysis of rHAPLN1 confirmed the functions of HAPLN1 in the activation of inflammation, proliferation, cell adhesion, and strengthening of ECM functions. Our results for the first time demonstrate the function of HAPLN1 in promoting the proliferation and pro-inflammatory phenotype of RA-FLSs, thereby contributing to RA pathogenesis. Future in-depth studies are required for better understanding the role of HAPLN1 in RA.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationFrontiers in Immunology, June 2022, v. 13, 888612en_US
dcterms.isPartOfFrontiers in immunologyen_US
dcterms.issued2022-06-
dc.identifier.scopus2-s2.0-85132284405-
dc.identifier.pmid35720292-
dc.identifier.eissn1664-3224en_US
dc.identifier.artn888612en_US
dc.description.validate202309 bcvc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOS-
dc.description.fundingSourceOthersen_US
dc.description.fundingTextChina Postdoctoral Science Foundation Project; National Natural Science Foundation of China; National Key Research and Development Programen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
fimmu-13-888612.pdf9.06 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

126
Last Week
4
Last month
Citations as of Nov 10, 2025

Downloads

48
Citations as of Nov 10, 2025

SCOPUSTM   
Citations

22
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

19
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.